We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Descemet's Stripping Preferred in Corneal Transplant Keratoplasty

By HospiMedica International staff writers
Posted on 08 Mar 2010
A new study suggests that the potential long-term benefits of Descemet's stripping automated endothelial keratoplasty (DSAEK) may outweigh the initial cell loss.

Researchers at Case Western Reserve University School of Medicine (Case Western; Cleveland, OH, USA) conducted a study to compare the outcomes of DSAEK in 173 subjects with a moderate risk condition (principally Fuchs' dystrophy or pseudophakic/aphakic corneal edema),with those of 410 subjects who underwent penetrating keratoplasty (PKP) and who had clear grafts with at least one postoperative specular image within a 15-month follow-up period. More...
The main outcome measures were endothelial cell density (ECD) and graft survival at one year. ECD was determined from baseline donor, 6-month, and 12-month postoperative central endothelial images.

The results showed that although the DSAEK recipient group criteria were similar to the PKP group, Fuchs' dystrophy was more prevalent in the DSAEK group and pseudophakic corneal edema was less prevalent. The researchers found that the results indicate cell loss in DSAEK patients plateau more quickly than in those who undergo PKP, and theorize that this is due to greater surgical manipulation of the donated graft itself. The researchers also found that preoperative diagnosis affected endothelial cell loss over time; in the PKP group, the subjects with pseudophakic/aphakic corneal edema experienced significantly higher 12-month cell loss than the subjects with Fuchs' dystrophy, whereas in the DSAEK group, the 12-month cell loss was comparable for the two diagnoses. The study was published in the March 2010 issue of Ophthalmology.

"There is no question of the immediate benefits of DSAEK,” said senior author Professor Jonathan Lass, M.D., chair of the department of ophthalmology and visual sciences at Case Western. "These benefits include greater eye integrity due to a smaller wound; quicker recovery with less visual distortion; and decreased severity in postoperative surface problems, such as dry eye. The fact that the transplants are less susceptible to trauma is promising for this growing procedure.”

DSEAK and PKP are alternative methods of corneal transplant surgery for diseases affecting the back cell layer of the cornea, the endothelium, when the cornea swells due to Fuchs' dystrophy or pseudophakic/aphakic corneal edema, conditions affecting the function of the corneal endothelium. Both the operation and recovery time associated with DSAEK are shorter, since the 360-degree PKP wound is larger, weaker, and more prone to rupture.

Related Links:
Case Western Reserve University School of Medicine



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.